Announcement on Preliminary Earnings Estimate for 2024
Filed with SSE · · 3 pages · Chinese
Suzhou Zelgen Biopharmaceuticals Co. Ltd. on 6ix
Earlier from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Platinum-based Chemotherapy Regimen
- Indicative Announcement on the Renewal of Concerted Action Agreement and Changes in Equity by Actual Controllers
- Annual Earnings Preannouncement for 2024
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Gecacitinib Hydrochloride Tablets
- Announcement on Voluntary Disclosure of Inclusion of Recombinant Human Thrombin into the Catalogue Of Drugs For Basic National Medical Insurance in 2024
Later from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Chemotherapy Regimen
- Announcement on Subproject Change, Amount Adjustment, and New Subprojects of Some Investment Projects Financed by Raised Funds
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint Inhibitor
- Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
- Announcement on Voluntary Disclosure of Acceptance of New Drug Marketing Application for Treatment of Severe Alopecia Areata with Gecacitinib Hydrochloride Tablets
Follow Suzhou Zelgen Biopharmaceuticals into a list and get an email when it puts out news.
Follow Suzhou Zelgen Biopharmaceuticals